The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05).

Sohei Satoi,Michiaki Unno,Fuyuhiko Motoi,Yutaka Matsuyama,Ippei Matsumoto,Suefumi Aosasa,Hirofumi Shirakawa,Keita Wada,Tsutomu Fujii,Hideyuki Yoshitomi,Shinichiro Takahashi,Masayuki Sho,Hideki Ueno,Tomohisa Yamamoto,Tomoo Kosuge

The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05).

2019

Sohei Satoi
Michiaki Unno
Fuyuhiko Motoi
Yutaka Matsuyama
Ippei Matsumoto
Suefumi Aosasa
Hirofumi Shirakawa
Keita Wada
Tsutomu Fujii
Hideyuki Yoshitomi
Shinichiro Takahashi
Masayuki Sho
Hideki Ueno
Tomohisa Yamamoto
Tomoo Kosuge

4126Background: Despite recent progress of adjuvant chemotherapy for resected pancreatic ductal adenocarcinoma (PDAC), its survival remains limited. We conducted a randomized controlled trial to co...

Keywords:

PHASE II/III TRIAL
Oncology
Pathology
Gemcitabine
Chemotherapy
Medicine
Internal medicine
Resectable Pancreatic Cancer
pancreatic ductal adenocarcinoma
Randomized controlled trial
adjuvant chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations